Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer

NCT00473083 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Rash

Interventions

DRUG: Minocycline
DRUG: Clindamycin 2% in hydrocortisone 1% lotion
DRUG: Erlotinib
DRUG: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln

Sponsor

British Columbia Cancer Agency

Collaborators

[object Object]